Hyperthermia combined with chemotherapy vs chemotherapy in patients with advanced pancreatic cancer:A multicenter retrospective observational comparative study  

作　　者：Giammaria Fiorentini Donatella Sarti Andrea Mambrini Ivano Hammarberg Ferri Massimo Bonucci Paola Giordano Sciacca Marco Ballerini Salvatore Bonanno Carlo Milandri Roberto Nani Stefano Guadagni Patrizia Dentico Caterina Fiorentini 

机构地区：[1]Integrative Oncology,Integrative Oncology Outpatient Clinic,Bologna 40121,Italy [2]Department of Oncology,Santa Maria della Misericordia Hospital,Urbino 60129,Italy [3]Department of Oncology,Azienda Sanitaria Locale Toscana Nord Ovest,Massa Carrara Hospital,Massa 54100,Italy [4]Integrative Oncology,Association Research Center for Integrative Oncology Treatments,Roma 00166,Italy [5]Complementary Medicine Service,District Hospital of Merano,Merano 39012,Italy [6]Hyperthermia Unit,Bellessere Medical Center,Terni 05100,Italy [7]Radiotherapy Unit,A.Rizza Hospital,Siracusa 96100,Italy [8]Medical Oncology,San Donato Hospital,Arezzo 52100,Italy [9]Interventional Radiology Unit,Humanitas Gavazzeni,Bergamo 24121,Italy [10]Applied Clinical Sciences and Biotechnology,Section of General Surgery,University of L'Aquila,L'Aquila 67100,Italy [11]Hyperthermia Service,Medical Oncology Unit,San Giuseppe Hospital,Empoli 50053,Italy [12]Prevention and Sports Medicine,University Hospital Klinikum rechts der Isar,Technical University of Munich,Munich 80331,Germany

出　　处：《World Journal of Clinical Oncology》2023年第6期215-226,共12页世界临床肿瘤学杂志（英文版）

摘　　要：BACKGROUND Several studies report the useful therapeutic results of regional hyperthermia in association with chemotherapy(CHT) and radiotherapy for the treatment of pancreatic cancer. Modulated electrohyperthermia(mEHT) is a new hyperthermia technique that induces immunogenic death or apoptosis of pancreatic cancer cells in laboratory experiments and increases tumor response rate and survival in pancreatic cancer patients, offering beneficial therapeutic effects against this severe type of cancer.AIM To assess survival, tumor response and toxicity of mEHT alone or combined with CHT compared with CHT for the treatment of locally advanced or metastatic pancreatic cancer.METHODS This was a retrospective data collection on patients affected by locally advanced or metastatic pancreatic cancer(stage Ⅲ and IV) performed in 9 Italian centers, members of International Clinical Hyperthermia Society-Italian Network. This study included 217 patients, 128(59%) of them were treated with CHT(no-mEHT) and 89(41%) patients received mEHT alone or in association with CHT. mEHT treatments were performed applying a power of 60-150 watts for 40-90 min, simultaneously or within 72 h of administration of CHT.RESULTS Median patients’ age was 67 years(range 31-92 years). mEHT group had a median overall survival greater than non-mEHT group(20 mo, range 1.6-24, vs 9 mo, range 0.4-56.25, P < 0.001). mEHT group showed a higher number of partial responses(45% vs 24%, P = 0.0018) and a lower number of progressions(4% vs 31%, P < 0.001) than the no-mEHT group, at the three months follow-up. Adverse events were observed as mild skin burns in 2.6% of mEHT sessions.CONCLUSION mEHT seems safe and has beneficial effects on survival and tumor response of stage Ⅲ-IV pancreatic tumor treatment. Further randomized studies are warranted to confirm or not these results.

关 键 词：Modulated electro hyperthermia Locally advanced pancreatic tumor Overall survival Tumor response GEMCITABINE Apoptosis Immunogenic cell death 

分 类 号：R735.9[医药卫生—肿瘤]